Adding Midostaurin to Intensive Chemotherapy in FLT3-Positive AML Patients. Results from a Multicenter Historical-Controlled Study
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-114154
Abstract: Introduction: The phase III RATIFY study (Stone et al, NEJM 2017) demonstrated that the addition of the FLT3 inhibitor midostaurin to intensive induction and consolidation courses improves outcome in younger FLT3-positive AML patients. The toxicity… read more here.
Keywords: control; midostaurin control; group; flt3 positive ... See more keywords